Lorlatinib-induced visual and auditory hallucinations: a case report
- jun hakamata,
- Hideo Nakada,
- Hiroshi Muramatsu,
- Keita Masuzawa,
- Hideki Terai,
- Shinnosuke Ikemura,
- Koichi Fukunaga,
- Tohru Aomori
Hideo Nakada
Keio University Faculty of Pharmacy Graduate School of Pharmacy
Author ProfileKeita Masuzawa
Keio University School of Medicine Graduate School of Medicine
Author ProfileShinnosuke Ikemura
Keio University School of Medicine Graduate School of Medicine
Author ProfileKoichi Fukunaga
Keio University School of Medicine Graduate School of Medicine
Author ProfileTohru Aomori
Keio University Faculty of Pharmacy Graduate School of Pharmacy
Author ProfileAbstract
Lorlatinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor
for the treatment of non-small-cell lung cancer. We report a case in
which visual and auditory hallucinations developed while receiving
lorlatinib.06 Nov 2020Submitted to Clinical Case Reports 12 Nov 2020Submission Checks Completed
12 Nov 2020Assigned to Editor
17 Nov 2020Reviewer(s) Assigned
22 Dec 2020Review(s) Completed, Editorial Evaluation Pending
24 Dec 2020Editorial Decision: Revise Minor
09 Feb 20211st Revision Received
12 Feb 2021Submission Checks Completed
12 Feb 2021Assigned to Editor
12 Feb 2021Review(s) Completed, Editorial Evaluation Pending
22 Feb 2021Editorial Decision: Accept
